Following U.S. Stocks are among the “Top Losers” Stocks in the course of recent trading session, Wednesday: Willbros Group Inc (NYSE:WG), Columbia Laboratories Inc (NASDAQ:CBRX), Sociedad Quimica y Minera de Chile (ADR) (NYSE:SQM), National Bank of Greece (ADR) (NYSE:NBG)
Willbros Group Inc (NYSE:WG)’s shares dwindled -52.19%, and is now trading at $2.64. The Stock is active as 6.55M shares changed hands versus its average volume of 346,006.00 shares. The stock has price to sale ratio of 0.13, however, price to book ratio is 1.85. With recent decline, the year-to-date (YTD) performance reflected a -12.60% decline below last year. During the past month the stocks fell -18.09%, bringing three-month performance to 28.64% and six-month performance to -45.15%. The mean recommendation of analysts for this stock is 3.20.(where 1=Buy, 5=Sale).
Willbros Group, Inc. operates as an energy infrastructure contractor serving the oil, gas, refinery, petrochemical, and power industries worldwide. The company provides engineering, procurement, and construction (EPC), turnarounds, maintenance, facilities development, and operations services to industry and government entities. Its Oil & Gas segment offers construction, project administration, maintenance, and lifecycle extension services to the upstream, midstream, and downstream markets.
Columbia Laboratories Inc (NASDAQ:CBRX), declined -15.22%, and is now trading at $6.46. The company holds the market capitalization of $69.48M. For the last twelve months, the stock was able to keep return on equity at 13.80%, while return on assets at 10.60%, in response to its return on investment at 11.40%. Its 20-day moving average declined -10.73%, above 50-day moving average of 2.99%, above 200-day moving average of 4.04% from the latest market price of $6.33. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Columbia Laboratories, Inc. provides pharmaceutical development, clinical trial manufacturing, and analytical and consulting services to the pharmaceutical industry. It focuses on the sale of CRINONE, a progesterone gel to its marketing partner. The company has licensed CRINONE to Merck Serono S.A. outside the United States; and has sold the /files/includes/pre-market-news-buzz-on-spirit-realty-capital-nysesrc-cloud-peak-energy-nysecld-analog-devices-nasdaqadi-ericsson-nasdaqeric-1522082-right.jss to CRINONE to Actavis, Inc. in the United States. Columbia Laboratories, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.
Sociedad Quimica y Minera de Chile (ADR) (NYSE:SQM), dipped -18.60%, and is now trading at $17.99, hitting new 52-week low of $18.45. The stock volatility for the week is 2.73%, while for the month remained 2.42%. The company holds consensus target price of $28.30.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 1.09 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -28.30% and Annual EPS growth for the past 5 years is considered as -1.40%.
The mean recommendation of analysts for this stock is 3.10. (where 1=Buy, 5=Sale).
Chemical and Mining Company of Chile Inc. is engaged in the production and distribution of specialty plant nutrients, iodine and its derivatives, lithium and its derivatives, potassium chloride and potassium sulfate, industrial chemicals, and other commodity fertilizers. The company’s specialty plant nutrients comprise potassium nitrate, sodium nitrate, sodium potassium nitrate, and specialty blends for crops, such as vegetables, fruits, and flowers, in addition to Ultrasol for application through fertigation; Qrop for field application; Speedfol for foliar application; and Allganic for organic farming. Its iodine and iodine derivatives are used in a range of medical, pharmaceutical, agricultural, and industrial applications, counting X-ray contrast media, polarizing films for liquid crystal displays, antiseptics, biocides and disinfectants in the synthesis of pharmaceuticals, herbicides, electronics, pigments, and dye components.
National Bank of Greece (ADR) (NYSE:NBG), dropped -9.62%, and is now trading at $1.17. The company has the market capitalization of $3.90B. The beta value of the stock is 2.49. On the other hand the stock’s volatility for the week is 6.48%, and for the month is 7.66%. The stock’s price to sale ratio is 0.81, however price to cash ratio is 0.37. Analyst’s mean recommendation regarding this stock is 3.00. (where 1=Buy, 5=Sale).
National Bank of Greece S.A., together with its subsidiaries, offers diversified financial services primarily in Greece. The company is involved in retail and commercial banking, investment administration, investment banking, insurance, investment activities, and securities trading activities. It offers demand deposits, savings deposits, and time deposits, and current accounts; investment products; consumer loans, personal loans, mortgage loans, automobile loans, overdraft facilities, and foreign currency loans, in addition to letters of credit and guarantees; credit cards; currency swaps and options; and ATMs. The company also provides financial and investment advisory services, foreign exchange, custody services, and trade finance services; and shipping finance, project finance, leasing, factoring, treasury, private banking, private equity, and brokerage services, in addition to asset administration, counting mutual funds and closed end funds.
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.